Review



anti-fxiia antibody garadacimab/csl-312 bio-similar  (ATUM Bio)


Bioz Verified Symbol ATUM Bio is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ATUM Bio anti-fxiia antibody garadacimab/csl-312 bio-similar
    Effect of <t>FXIIa</t> inhibition on contact pathway–initiated TG in PK-sufficient and -deficient WB. Representative curves of silica-initiated TG in Klkb1 +/+ (A) and Klkb1 – / – (B) mouse WB in the presence of increasing concentrations of the inhibitory anti-FXIIa antibody garadacimab. Quantification of TG lag time (C) and peak TG (D) in Klkb1 +/+ or Klkb1 – / – mouse WB in the presence of 50 μg/mL garadacimab or IgG control (n = 3-5 per group). Data presented as individual values with mean ± SD. Data analyzed with paired Student t tests comparing samples with and <t>without</t> <t>inhibitor;</t> ∗∗ P < .01. Gara, garadacimab; ns, not signficant.
    Anti Fxiia Antibody Garadacimab/Csl 312 Bio Similar, supplied by ATUM Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-312+antibody/anti+fxiia+antibody+garadacimab+++csl+312+bio+similar/pmc11215197-42-19-23
    Average 90 stars, based on 1 article reviews
    anti-fxiia antibody garadacimab/csl-312 bio-similar - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood"

    Article Title: Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood

    Journal: Blood Advances

    doi: 10.1182/bloodadvances.2024012613

    Effect of FXIIa inhibition on contact pathway–initiated TG in PK-sufficient and -deficient WB. Representative curves of silica-initiated TG in Klkb1 +/+ (A) and Klkb1 – / – (B) mouse WB in the presence of increasing concentrations of the inhibitory anti-FXIIa antibody garadacimab. Quantification of TG lag time (C) and peak TG (D) in Klkb1 +/+ or Klkb1 – / – mouse WB in the presence of 50 μg/mL garadacimab or IgG control (n = 3-5 per group). Data presented as individual values with mean ± SD. Data analyzed with paired Student t tests comparing samples with and without inhibitor; ∗∗ P < .01. Gara, garadacimab; ns, not signficant.
    Figure Legend Snippet: Effect of FXIIa inhibition on contact pathway–initiated TG in PK-sufficient and -deficient WB. Representative curves of silica-initiated TG in Klkb1 +/+ (A) and Klkb1 – / – (B) mouse WB in the presence of increasing concentrations of the inhibitory anti-FXIIa antibody garadacimab. Quantification of TG lag time (C) and peak TG (D) in Klkb1 +/+ or Klkb1 – / – mouse WB in the presence of 50 μg/mL garadacimab or IgG control (n = 3-5 per group). Data presented as individual values with mean ± SD. Data analyzed with paired Student t tests comparing samples with and without inhibitor; ∗∗ P < .01. Gara, garadacimab; ns, not signficant.

    Techniques Used: Inhibition, Control

    Related Articles

    Fluorescence:

    Article Title: Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood
    Article Snippet: The affinity of CSL-312 for FXIIa was confirmed by homogeneous time-resolved fluorescence and inhibitory activity in activated partial thromboplastin time assays in pooled human plasma (ATUM Bio).

    Activity Assay:

    Article Title: Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood
    Article Snippet: The affinity of CSL-312 for FXIIa was confirmed by homogeneous time-resolved fluorescence and inhibitory activity in activated partial thromboplastin time assays in pooled human plasma (ATUM Bio).

    Clinical Proteomics:

    Article Title: Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood
    Article Snippet: The affinity of CSL-312 for FXIIa was confirmed by homogeneous time-resolved fluorescence and inhibitory activity in activated partial thromboplastin time assays in pooled human plasma (ATUM Bio).



    Similar Products

    anti-fxiia antibody garadacimab/csl-312 bio-similar  (ATUM Bio)
    90
    ATUM Bio anti-fxiia antibody garadacimab/csl-312 bio-similar
    Effect of <t>FXIIa</t> inhibition on contact pathway–initiated TG in PK-sufficient and -deficient WB. Representative curves of silica-initiated TG in Klkb1 +/+ (A) and Klkb1 – / – (B) mouse WB in the presence of increasing concentrations of the inhibitory anti-FXIIa antibody garadacimab. Quantification of TG lag time (C) and peak TG (D) in Klkb1 +/+ or Klkb1 – / – mouse WB in the presence of 50 μg/mL garadacimab or IgG control (n = 3-5 per group). Data presented as individual values with mean ± SD. Data analyzed with paired Student t tests comparing samples with and <t>without</t> <t>inhibitor;</t> ∗∗ P < .01. Gara, garadacimab; ns, not signficant.
    Anti Fxiia Antibody Garadacimab/Csl 312 Bio Similar, supplied by ATUM Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-312+antibody/anti+fxiia+antibody+garadacimab+++csl+312+bio+similar/pmc11215197-42-19-23
    Average 90 stars, based on 1 article reviews
    anti-fxiia antibody garadacimab/csl-312 bio-similar - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    csl-312 antibody  (ATUM Bio)
    90
    ATUM Bio csl-312 antibody
    Effect of <t>FXIIa</t> inhibition on contact pathway–initiated TG in PK-sufficient and -deficient WB. Representative curves of silica-initiated TG in Klkb1 +/+ (A) and Klkb1 – / – (B) mouse WB in the presence of increasing concentrations of the inhibitory anti-FXIIa antibody garadacimab. Quantification of TG lag time (C) and peak TG (D) in Klkb1 +/+ or Klkb1 – / – mouse WB in the presence of 50 μg/mL garadacimab or IgG control (n = 3-5 per group). Data presented as individual values with mean ± SD. Data analyzed with paired Student t tests comparing samples with and <t>without</t> <t>inhibitor;</t> ∗∗ P < .01. Gara, garadacimab; ns, not signficant.
    Csl 312 Antibody, supplied by ATUM Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-312+antibody/anti+fxiia+antibody+garadacimab+++csl+312+bio+similar/pmc11215197-44-3-25
    Average 90 stars, based on 1 article reviews
    csl-312 antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    anti-fxiia antibody garadacimab / csl-312 bio-similar  (ATUM Bio)
    90
    ATUM Bio anti-fxiia antibody garadacimab / csl-312 bio-similar
    Effect of <t>FXIIa</t> inhibition on contact pathway–initiated TG in PK-sufficient and -deficient WB. Representative curves of silica-initiated TG in Klkb1 +/+ (A) and Klkb1 – / – (B) mouse WB in the presence of increasing concentrations of the inhibitory anti-FXIIa antibody garadacimab. Quantification of TG lag time (C) and peak TG (D) in Klkb1 +/+ or Klkb1 – / – mouse WB in the presence of 50 μg/mL garadacimab or IgG control (n = 3-5 per group). Data presented as individual values with mean ± SD. Data analyzed with paired Student t tests comparing samples with and <t>without</t> <t>inhibitor;</t> ∗∗ P < .01. Gara, garadacimab; ns, not signficant.
    Anti Fxiia Antibody Garadacimab / Csl 312 Bio Similar, supplied by ATUM Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-312+antibody/anti+fxiia+antibody+garadacimab+++csl+312+bio+similar/pm38593231-73-19-25
    Average 90 stars, based on 1 article reviews
    anti-fxiia antibody garadacimab / csl-312 bio-similar - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Effect of FXIIa inhibition on contact pathway–initiated TG in PK-sufficient and -deficient WB. Representative curves of silica-initiated TG in Klkb1 +/+ (A) and Klkb1 – / – (B) mouse WB in the presence of increasing concentrations of the inhibitory anti-FXIIa antibody garadacimab. Quantification of TG lag time (C) and peak TG (D) in Klkb1 +/+ or Klkb1 – / – mouse WB in the presence of 50 μg/mL garadacimab or IgG control (n = 3-5 per group). Data presented as individual values with mean ± SD. Data analyzed with paired Student t tests comparing samples with and without inhibitor; ∗∗ P < .01. Gara, garadacimab; ns, not signficant.

    Journal: Blood Advances

    Article Title: Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood

    doi: 10.1182/bloodadvances.2024012613

    Figure Lengend Snippet: Effect of FXIIa inhibition on contact pathway–initiated TG in PK-sufficient and -deficient WB. Representative curves of silica-initiated TG in Klkb1 +/+ (A) and Klkb1 – / – (B) mouse WB in the presence of increasing concentrations of the inhibitory anti-FXIIa antibody garadacimab. Quantification of TG lag time (C) and peak TG (D) in Klkb1 +/+ or Klkb1 – / – mouse WB in the presence of 50 μg/mL garadacimab or IgG control (n = 3-5 per group). Data presented as individual values with mean ± SD. Data analyzed with paired Student t tests comparing samples with and without inhibitor; ∗∗ P < .01. Gara, garadacimab; ns, not signficant.

    Article Snippet: In some experiments, samples were supplemented with the small molecule PKa inhibitor berotralstat (MedChem Express, Monmouth Junction, NJ), an anti-FXIIa antibody (garadacimab/CSL-312 bio-similar; ATUM Bio, Newark, CA), an anti-PKa antibody (lanadelumab bio-similar; ProteoGenix USA, Miami, FL), an anti-TF antibody (1H1; Genentech, San Francisco, CA), or appropriate vehicle and immnuoglubulin G (IgG) controls.

    Techniques: Inhibition, Control